Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-373P represents a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family[4][5]. U6 snRNA itself is an essential component of the spliceosome, contributing critically to the excision of introns from pre-mRNA during pre-mRNA splicing[1][3]. However, pseudogenes such as RNU6-373P are generally regarded as genomic elements that resemble functional genes (in this case, U6 snRNA genes) but have lost their original function due to mutations, rearrangements, or truncations[4][5]. These pseudogenes are non-coding and are not transcribed into functional snRNA, and their presence is believed to result from evolutionary duplication and alteration processes. No evidence supports a functional, regulatory, or therapeutic role for RNU6-373P specifically. Thus, it is not considered a drug target, and there are no established interacting drugs, biomarkers, or safety concerns attributed to it. Further research into non-coding RNA pseudogenes is ongoing in genomics, but for RNU6-373P, direct biological or clinical relevance is not currently established[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 373, pseudogene (RNU6-373P).